Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.44 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641307 | 0.86 | EGLN1 (0.56) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1641593 | 0.86 | EGLN1 (0.47) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1642647 | 0.85 | EGLN1 (0.49) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1642476 | 0.84 | EGLN1 (0.47) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1641077 | 0.83 | EGLN1 (0.60) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1642588 | 0.83 | EGLN1 (0.47) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1642767 | 0.83 | EGLN1 (0.45) | EGLN1EGLN3KMT2A | |
| SCHEMBL1642648 | 0.82 | EGLN1 (0.46) | EGLN1EGLN3KMT2A | |
| SCHEMBL1642978 | 0.79 | EGLN1 (0.43) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL1642217 | 0.78 | EGLN1 (0.67) | EGLN1EGLN3OGFOD1EGLN2HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885OGFOD1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.